First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort
← catalyst calendarSponsored by Satellos Bioscience, Inc. (industry) · MSLE — their whole pipeline →.
Phase
Early Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
77actual
Sites
2
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-21 | actual | When the study began enrolling |
| Primary completion | 2025-04-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-28 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Duchenne Muscular Dystrophy
Interventions
- Drug: SAT-3247 — also filed as SAT3247, AAK1 inhibitor
- Drug: matched placebo — also filed as placebo
Primary outcome
what the primary-completion date above is the date OFIncidence and severity of treatment emergent adverse events
measured Part A: Day 1-3; Part B: Day 1-8; Part C: Day 1-3; Part D: Day 1-28
Permalink · MSLE's whole pipeline · Catalyst calendar · Every registered study · What changed